Life Expectancy and Settlement Pricing: The Core Relationship

The DCF Skeleton: Three Inputs, One Dominant Variable

Strip away the paperwork and every settlement offer reduces to one equation. The buyer — a licensed provider deploying institutional capital from pension funds, asset managers, and insurance-linked securities funds — values a policy as:

Offer ≈ Present value of the death benefit − Present value of expected future premiums − Transaction costs and required margin

Three inputs drive it:

• The premium stream. How much must be paid, and for how long, to keep the policy in force. Buyers typically re-engineer the policy to minimum funding, but the schedule is fundamentally a feature of the contract.
• The discount rate. The buyer’s required return, set by its cost of capital and the risk of the asset class. Because settlement returns are driven by mortality experience rather than markets, they are prized for being non-correlated with equities — but the rates are still meaningfully high, which is why distant cash flows shrink fast.
• The timing assumption — life expectancy. When, probabilistically, the death benefit arrives and the premium obligation stops.

The first two inputs vary modestly across buyers and policies. The third varies enormously across insureds — from under 24 months to over 20 years — and it appears on both sides of the equation: longer life expectancy simultaneously pushes the death benefit further away (shrinking its present value) and stacks up more premiums (growing the cost side). That double action is why life expectancy dominates pricing, and why the offer curve behaves the way the next section describes. The health inputs feeding the estimate are covered in how health affects life settlement value.

Why the Offer Curve Is Steep, Not Straight

Sellers often assume value moves proportionally — half the life expectancy, roughly double the offer. The reality is sharper: offers rise faster than linearly as life expectancy shortens, for three compounding reasons.

• Discounting is exponential. At institutional discount rates, a death benefit expected in 15 years is worth only a fraction of one expected in 5 years, which is itself worth much less than one expected in 2. Each year removed from the horizon restores value at an accelerating rate.
• Premiums stack linearly but hit hardest at the long end. Every additional year of life expectancy adds another year of premiums — often on policies where costs of insurance rise steeply at advanced ages. Long-LE files can see projected premiums consume most of the death benefit’s present value, which is why offers on healthy insureds frequently cannot beat surrender value.
• Uncertainty penalties shrink. Long estimates carry wide error bands, and buyers price that risk with margin. Short, well-documented estimates — especially terminal certifications — are tighter, so less value is held back.

The market data reflect the curve’s shape. The GAO’s study found settlements paying roughly 10–35% of face value, typically four to eight times cash surrender value — with position in the band tracking life expectancy. Below roughly 24 months, transactions become viatical, several states impose minimum payout percentages scaled to LE bands, and offers can exceed the standard range entirely.

One practical corollary: small changes in the LE estimate produce large changes in the offer — a 20% shorter estimate can move an offer far more than 20%. That sensitivity is why the underwriting process, covered next, deserves a seller’s full attention.

Inside a Life Expectancy Report: Method, Not Prophecy

The life expectancy estimate is manufactured by specialized underwriting firms, and understanding their product demystifies the whole market. A standard transaction uses two independent reports, taking two to six weeks — the full process is described in our guide to independent LE reports. The essentials:

• Base table. The underwriter starts from an actuarial mortality table appropriate to the insured’s age, sex, and smoking status.
• Debit-credit adjustment. Each documented impairment adds mortality debits (multipliers); favorable factors — strong functional status, well-controlled conditions, family longevity — add credits. The adjusted mortality multiple might be 150%, 300%, or far higher for severe multi-system disease.
• Survival curve output. Applying the adjusted mortality to the table produces a personalized survival curve. The headline “life expectancy” is usually the median — the month by which cumulative death probability reaches 50%. Sophisticated buyers price the entire curve, not just the median, because a policy pays off along a distribution, not on a date.
• It is an estimate of a population, not a prophecy about a person. An LE of 60 months means half of statistically similar individuals would pass within 60 months — it says nothing certain about any single life. Individuals outlive and underlive their estimates constantly; the protease-inhibitor era of the HIV viatical market remains the historic proof.

Reports from different firms routinely diverge — methodologies, debit manuals, and philosophies differ — and buyers blend or take the more conservative. Sellers are entitled to ask what LE assumptions underlie their offers, and should. An offer is only as sound as the estimate beneath it.

Underwritten Life Expectancy	Buyer’s Premium Burden	Typical Pricing Outcome	Legal / Tax Framework
15+ years	Very heavy — often consumes the death benefit’s present value	Frequently no offer above cash surrender value	Ordinary settlement rules; Rev. Rul. 2009-13 if sold
10–15 years	Heavy	Low end of the 10–35%-of-face band, when marketable	Ordinary settlement; three-tier tax treatment
5–10 years	Moderate	Mid-band; typically 4–8× cash surrender value; competition most valuable here	Ordinary settlement; three-tier tax treatment
2–5 years	Light	Upper band	May qualify as chronic-illness viatical if ADL/cognitive criteria met
Under 24 months (certified)	Minimal	Strongest offers; can exceed the standard band; state minimum payouts may apply	Viatical settlement; proceeds often income-tax-free under IRC 101(g)

Worked Example: One Policy, Three Life Expectancies

To make the relationship concrete, consider a single illustrative policy — $400,000 universal life, annual premium requirement around $14,000, insured age 74 — priced under three medical scenarios. (Numbers are directional illustrations, not quotes; every real file prices individually.)

• Scenario A — LE ~14 years (healthy). The buyer projects roughly $196,000 of premiums and waits well over a decade for a heavily discounted death benefit. The DCF often produces a value below cash surrender value — no market offer, or a nominal one. The seller’s real comparison becomes settlement versus surrender or holding.
• Scenario B — LE ~6 years (multiple significant impairments). Projected premiums fall near $84,000 and the death benefit sits close enough for discounting to spare much of its value. Offers plausibly land in the mid-teens to high-20s as a percentage of face — squarely inside the GAO-documented band, and typically several multiples of surrender value. Competitive bidding among providers matters most in this zone, where buyer models disagree the most.
• Scenario C — LE ~14 months (terminal certification). The premium projection nearly vanishes and the death benefit is discounted only briefly. The transaction is now a viatical settlement: state minimum-payout rules may apply, offers can exceed the standard range substantially, and proceeds are often income-tax-free under IRC 101(g) — the framework in our complete viatical guide. The seller should also obtain the carrier’s accelerated death benefit quote before selling, since the rider may pay comparably while preserving part of the benefit for family.

Same policy, same face amount — three entirely different markets, separated only by life expectancy.

The 24-Month Threshold: Where Pricing Meets the Tax Code

One point on the life expectancy spectrum carries legal weight far beyond pricing: 24 months.

When a physician certifies an illness or condition reasonably expected to result in death within 24 months, the insured is “terminally ill” for two distinct bodies of law:

• State settlement law. The transaction becomes a viatical settlement under most state statutes built on the NAIC model framework — triggering, in several states, minimum payout percentages scaled to life expectancy, plus the standard protections of licensing, escrow, disclosure, and 15–30 day rescission windows. Qualification details are in who qualifies for a viatical settlement.
• Federal tax law. Under IRC Section 101(g), proceeds paid to a terminally ill insured by a licensed viatical settlement provider are treated as death benefits — generally excluded from income entirely. Compare the default: IRS Rev. Rul. 2009-13’s three-tier treatment (basis tax-free; basis-to-CSV ordinary income; excess capital gain), detailed in our tax treatment guide. A parallel, narrower exclusion covers chronically ill insureds — two-plus ADL deficits or severe cognitive impairment — limited to long-term care costs and per-diem caps; see the viatical tax exclusion guide.

For sellers near the threshold, the implications are practical: the certification must be in writing and kept with tax records; the buyer’s provider license should be verified with the state insurance department — in New Jersey, the NJ DOBI; and classification should never be left to default, because on a large policy the tax difference alone can exceed the spread between competing offers. The pricing curve and the legal threshold interact: the same short life expectancy that maximizes the gross offer also maximizes the after-tax advantage.

What Sellers Control: Making the Estimate Match Reality

A seller cannot choose their life expectancy — but they exert real influence over whether the underwritten estimate reflects it. Because pricing is hypersensitive to the LE input, this influence is worth money.

• Feed the model complete records. Underwriters price only what the documents prove. Records requested under your HIPAA authorizations (see the medical records release guide) should span every treating provider — primary care, cardiology, oncology, neurology — because each chart holds different debits. Missing charts mean missing debits, an inflated LE, and a deflated offer.
• Refresh before underwriting. Estimates discount stale information. A current specialist visit documenting present status, progression, and functional decline (ADL assistance, mobility aids, weight loss, falls, care hours) sharpens the estimate in the direction of accuracy.
• Re-underwrite after health events. A significant new diagnosis or hospitalization is a repricing event. Old quotes — and old LE reports, which typically go stale after 6–12 months — should not anchor a current decision.
• Interrogate the offers. Ask each bidder what LE it used. Wildly divergent offers usually mean divergent LE assumptions; understanding which report drove which bid tells you whether to fix the file or push the bidding.
• Force competition. With the LE fixed, the remaining offer spread comes from buyers’ discount rates and margins — compressible only through multiple licensed bidders or a licensed broker whose compensation you see in dollars.

And keep the policy alive throughout: the 60–120 day process, with LE reports consuming two to six weeks, only ends well if premiums stay current — the 30–31 day grace period is a backstop, and the premium-hardship options exist for genuine emergencies.

The Estimate Can Be Wrong — In Both Directions

An honest treatment of life expectancy pricing ends with its uncertainty, because both sides of the transaction live with it after closing.

If the insured outlives the estimate, the buyer pays more premiums and waits longer — that is the buyer’s risk, priced into its margin. The seller keeps every dollar received; nothing is owed back. But the seller’s family has permanently surrendered a death benefit that, in hindsight, sat further away than the price assumed. This is not hypothetical: medical breakthroughs have historically rewritten prognoses — most famously when antiretroviral therapy transformed the HIV viatical market in 1996 — and individual outcomes routinely beat median estimates, since half of any cohort does. A seller beginning a promising new therapy should weigh the timing of underwriting consciously.

If the insured underlives the estimate, the buyer collects early and the seller’s family may feel, painfully, that the policy was sold too cheap. The rescission provisions in most state laws — 15 to 30 days, often with automatic unwinding if the insured dies within the window — exist precisely to soften the sharpest version of this outcome.

Neither direction can be predicted, which is why the disciplined comparison is never “offer versus estimate” but “offer versus alternatives”: the carrier’s accelerated death benefit quote, policy loans against cash value, reduced paid-up coverage, holding to maturity if premiums are sustainable — and the effect of a lump sum on means-tested benefits like Medicaid, addressed in our spend-down guide. Life expectancy sets the price; the alternatives determine whether the price is worth taking. For the seniors’ version of that full decision, see our life settlements guide for seniors.

---

Frequently Asked Questions

How exactly does life expectancy determine a life settlement offer?

Through a discounted cash flow calculation. The buyer subtracts the present value of every premium it expects to pay from the present value of the death benefit it expects to collect, and life expectancy controls both: a shorter estimate means fewer premiums and a sooner, less-discounted benefit. Because it acts on both sides of the equation simultaneously, life expectancy dominates pricing — more than face amount, cash value, or any other single input in the model.

Why do life settlement offers rise so sharply when life expectancy is short?

Three effects compound. Discounting is exponential, so each year removed from the payoff horizon restores value at an accelerating rate. Premium projections shrink year for year — and cost-of-insurance charges are steepest at advanced ages, so the years that disappear are the expensive ones. And shorter, well-documented estimates carry tighter error bands, so buyers hold back less margin for uncertainty. Together these make the offer curve steep rather than proportional as life expectancy falls.

What is a life expectancy report and who prepares it?

It is a medical-actuarial estimate prepared by specialized independent underwriting firms, typically two per transaction, taking two to six weeks. Underwriters start from an actuarial mortality table for the insured’s age and sex, apply debits for each documented impairment and credits for favorable factors, and produce a personalized survival curve — summarized as a median life expectancy in months. Buyers price from these reports, which is why complete, current medical records directly affect what you are offered.

Why is 24 months such an important life expectancy number in settlements?

Because it is written into both state and federal law. A physician certification of life expectancy within 24 months makes the insured terminally ill, converting the sale into a viatical settlement — which triggers minimum payout percentages in several states and, under IRC Section 101(g), generally makes the proceeds income-tax-free when the buyer is a licensed provider. The same short life expectancy that produces the strongest gross offer also produces the best tax outcome, so proper classification matters enormously.

Can two life expectancy reports on the same person be different?

Routinely — and the divergence is normal, not a red flag. Underwriting firms use different debit manuals, methodologies, and philosophies, so the standard two reports rarely match; buyers typically average them or price from the more conservative. For sellers, the lesson is to ask what estimate underlies each offer. If bids diverge widely, divergent LE assumptions are usually why, and it may signal that one underwriter lacked records the other had.

What happens to a life settlement if the insured lives longer than the life expectancy estimate?

Nothing changes for the seller — the money received is theirs, no adjustment or repayment exists, and the buyer simply pays premiums longer and collects later. Longevity risk is the buyer’s, priced into its margin. The seller’s real exposure is retrospective: the family permanently gave up a death benefit that turned out to be further away than the price assumed. History’s famous example is the 1996 protease-inhibitor breakthrough, when HIV viatical sellers mercifully outlived estimates by decades.

Why might a healthy person get no life settlement offer at all?

Because the math fails. At life expectancies of fifteen-plus years, the buyer must fund premiums for a very long time — often at ages where cost-of-insurance charges climb steeply — while the death benefit sits so far out that exponential discounting shrinks it drastically. The resulting value frequently lands below the policy’s own cash surrender value, so no rational offer can beat what the carrier already owes you. Health impairments, not policy size, are what move a file into marketable territory.

How can I make sure my life expectancy estimate is accurate before selling?

Control the record. Ensure underwriters receive charts from every treating provider, since each holds different mortality debits; refresh documentation with current specialist visits that capture progression and functional status — ADL help, mobility aids, weight changes, falls; and re-underwrite after any significant health event, because estimates and quotes go stale. Then ask every bidder which life expectancy its offer assumes. An estimate that reflects a healthier person than reality systematically underprices your policy.

Related Reading

• How Health Affects Life Settlement Value
• Independent Life Expectancy Reports
• Viatical Settlement Complete Guide
• Life Settlement Tax Treatment Guide

---

Pine Lake Life Solutions does not purchase life insurance policies and does not provide legal, tax, or investment advice. Information provided is for educational purposes only. Eligibility for any option, including life settlements, is not guaranteed and depends on individual circumstances, policy terms, underwriting, and market conditions. Consult independent legal, tax, or financial professionals before making decisions regarding a life insurance policy.